Initial Management of <i>BRAF </i>V600E-Variant Anaplastic Thyroid Cancer
Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Priyanka Iyer(The University of Texas MD Anderson Cancer Center), Mark Zafereo(Texas Medical Center), G. Brandon Gunn(The University of Texas MD Anderson Cancer Center), Neal S. Akhave(The University of Texas MD Anderson Cancer Center), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Jennifer Wang(The University of Texas MD Anderson Cancer Center), Luana Guimarães de Sousa(The University of Texas MD Anderson Cancer Center), Anastasios Maniakas(The University of Texas MD Anderson Cancer Center), Kim O. Learned(The University of Texas MD Anderson Cancer Center), Michelle D. Williams(The University of Texas MD Anderson Cancer Center), S. Mohsen Hosseini(University of Toronto), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Stephen Y. Lai(The University of Texas MD Anderson Cancer Center), Michael T. Spiotto(The University of Texas MD Anderson Cancer Center), Anna Lee(The University of Texas MD Anderson Cancer Center), Salmaan Ahmed(The University of Texas MD Anderson Cancer Center), Charles Lu(The University of Texas MD Anderson Cancer Center), Renata Ferrarotto(The University of Texas MD Anderson Cancer Center)
Cited by 35
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766